Search

Displaying results 631 - 640 of 6198 in total
  1. Drug

    Janssen COVID-19 Vaccine

    go.drugbank.com/drugs/DB15857
    ApprovedInvestigational

    The Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … Follow-up preclinical studies in rhesus monkeys[A220058] showed that the Ad26 vaccine produced a robust response and provided near perfect protection in nasal swabs and bronchoalveolar lavage following

  2. Drug

    Aminolevulinic acid

    go.drugbank.com/drugs/DB00855
    ApprovedInvestigational

    A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]

  3. Drug

    Oxycodone

    go.drugbank.com/drugs/DB00497
    ApprovedIllicitInvestigational

    [Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460] … for an extended period.

    Products: Ran-oxycodone CR
  4. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … [L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703]

  5. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    The recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081]. … Xylitol is a non-fermentable sugar alcohol by most plaque bacteria, indicating that it cannot be fermented into cariogenic acid end-products [A32423].

  6. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    [A243351, A243356, L39411] As the RBD binding site of tixagevimab does not overlap with that of [cilgavimab], the two can be administered to synergistically impair SARS-CoV-2 infection in individuals who … [A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA.

  7. Drug

    Tizanidine

    go.drugbank.com/drugs/DB00697
    ApprovedInvestigational

    It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. … Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons

  8. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.

  9. Drug

    Gelatin

    go.drugbank.com/drugs/DB11242
    ApprovedInvestigationalVet approvedWithdrawn

    An increasing number of novel applications have been found for collagen and gelatin.[A32426] Gelatin is generally recognized as safe (GRAS) by the FDA to be a non-hazardous food or food ingredient. … [A32432] Some alternative raw substances have recently garnered attention from both researchers and the industry not only because they overcome religious concerns shared by both Jews and Muslims but

  10. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]